A next-gen antibody drug conjugate: Blend rakes in $21M for new anticancer platform
Massachusetts biotech Blend Therapeutics just raked in $21 million to advance its a new, and rather interesting, class of cancer therapeutics. It’s using the dollars to grow its Pentarin platform, which creates novel, miniature biologic drug conjugates that are encapsulated in nanoparticles. The funding will also help advance a separate drug candidate, BTP-114, closer to the […]